[1] |
WANG Qing, YU Yushuai, WANG Chenxi, JIANG Zirong, LI Jialu, TANG Shicong, SONG Chuangui.
Current status and prospects of tertiary lymphoid structure heterogeneity in predicting response to neoadjuvant therapy and characterizing immune microenvironment in triple-negative breast cancer
[J]. China Oncology, 2025, 35(2): 213-218.
|
[2] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[3] |
Society of Neuroendocrine Neoplasm of China Anti-Cancer Association.
China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)
[J]. China Oncology, 2025, 35(1): 85-142.
|
[4] |
LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan.
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
[J]. China Oncology, 2024, 34(4): 368-379.
|
[5] |
KE Zhui, GAO Jie, LU Jingyi, LUO Xinpei, HE Xuemin, LIU Zhuqing, YUAN Min, GUO Xianling, XU Qing.
A prospective single-arm study of the efficacy and safety of lobaplatin-based HIPEC combined with optimal support in the treatment of abdominal metastatic cancer
[J]. China Oncology, 2024, 34(12): 1115-1122.
|
[6] |
LI Xinran, LIANG Yiyi, TU Hong.
Research progress of the intratumoral microbiome
[J]. China Oncology, 2023, 33(9): 866-873.
|
[7] |
ZHANG Shaoqiu, YAN Li, LI Ruichen, ZHAO Yang, WANG Xiaoshen, YANG Xuguang, ZHU Yi.
Recent advances and prospect in immune microenvironment and its mechanisms of function in head and neck squamous cell carcinoma
[J]. China Oncology, 2023, 33(6): 629-636.
|
[8] |
ZUO Xueliang, CHEN Zhiqiang, DONG Runyu, WANG Zhixiong, CAI Juan.
The value of combined detection of LDHA and PD-L1 in predicting the efficacy and prognosis of advanced gastric cancer patients treated with PD-1 inhibitor
[J]. China Oncology, 2023, 33(5): 460-468.
|
[9] |
YANG Wenxiao, GUO Linwei, LING Hong, HU Xin.
Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy
[J]. China Oncology, 2023, 33(5): 484-498.
|
[10] |
GAO Heli, XU Jin, CHEN Jie, YU Xianjun.
Updates on precision medicine of pancreatic neuroendocrine tumor
[J]. China Oncology, 2023, 33(11): 993-1001.
|
[11] |
YANG Wenbo, ZHANG Bin, WU Jiahui, CUI Jie.
Current status and treatment direction of the immune microenvironment of castration-resistant prostate cancer
[J]. China Oncology, 2023, 33(10): 945-953.
|
[12] |
LIU Xueping, MU Nai, LI Xiaochun, WANG Ruisi, TAN Bangxian.
Gingival metastasis from primary hepatocellular carcinoma: a case report
[J]. China Oncology, 2023, 33(1): 78-80.
|
[13] |
LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie.
Updates on medical treatment for neuroendocrine neoplasm
[J]. China Oncology, 2022, 32(9): 757-764.
|
[14] |
WANG Xianze, WU Wenming.
Evolution in the surgical treatment concepts of pancreatic neuroendocrine tumors
[J]. China Oncology, 2022, 32(9): 765-771.
|
[15] |
CUI Lingjun, TIAN Chao, CHENG Zixuan, ZHENG Jiabin, SU Fei, TAN Huangying.
Advances in preclinical research models for gastroenteropancreatic neuroendocrine neoplasm
[J]. China Oncology, 2022, 32(9): 779-785.
|